Amezalpat has been granted FDA fast track designation as treatment for patients with hepatocellular carcinoma.

The firm will study its autologous cell therapy alone and in combination with Eisai's Lenvima in patients with hepatitis B-driven hepatocellular carcinoma.

Exelixis, Inc. EXEL reported better-than-expected fourth-quarter results. EXEL recorded earnings of 55 cents per share, which beat the Zacks Consensus Estimate of 51 cents. The company registered ...

Rights Mar 15, 2024 Mar 16, 2024 Aug 03, 2023 Rights ratio: 13 share for every 118 held at a price of Rs 21.0 Rights Nov 20, 2018 Nov 22, 2018 Sep 05, 2018 Rights ratio: 49 share for every 100 held at ...